fbpx
01 / 05
“Inverse Vaccine” Shows Potential to Treat Autoimmune Diseases

University of Chicago | Vaccination

“Inverse Vaccine” Shows Potential to Treat Autoimmune Diseases

“A new type of vaccine developed by researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) has shown in the lab setting that it can completely reverse autoimmune diseases like multiple sclerosis and type 1 diabetes — all without shutting down the rest of the immune system.”

From University of Chicago.

Medical Xpress | Noncommunicable Disease

New Imaging Set to Accelerate Cardiovascular Medicine

“Two whole adult human hearts, one healthy and one diseased, have been imaged in unprecedented detail by researchers from UCL and the European Synchrotron Radiation Facility (ESRF), providing an invaluable resource for better understanding cardiovascular disease.

The study, published in Radiology, is an atlas of the human heart that captures the anatomical structure of the whole organ down to 20 micrometers—half the width of a human hair. In certain areas imaging has been done to the cellular level.

The atlas will facilitate previously impossible research into both healthy and diseased hearts, clarifying anatomical structures and connections within the organ, with potential applications ranging from improving the treatment for arrythmia to creating more lifelike models for surgical training.”

From Medical Xpress.

The Guardian | Vaccination

First Asian Elephant Vaccinated in Fight against Deadly Herpes Virus

“An Asian elephant at Houston zoo in the US has received the first mRNA vaccine against herpes, which is the leading killer of Asian elephants calves in captivity.

Tess, a 40-year-old Asian elephant, was injected with the trial vaccine at the Texas zoo in June, after a spate of deaths in juveniles in zoos around the world from the elephant endotheliotropic herpesvirus (EEHV).

Dr Paul Ling, who researches herpes in humans at Baylor College of Medicine in Houston, developed the elephant mRNA vaccine, which is designed to boost the immunity of young elephants.”

From The Guardian.

CNN | Vaccination

Children Receive First Doses of New Malaria Vaccine

“Children in Ivory Coast received the first doses of a new, relatively cheap malaria vaccine on Monday, a step that has been hailed as a major milestone in the battle against one of the world’s most deadly diseases.

The R21 vaccine, developed by the Jenner Institute at the University of Oxford and the Serum Institute of India (SII), has been sent to several African countries and will also be administered in South Sudan Tuesday, the University of Oxford said in a statement sent to CNN.

The vaccine costs less than $4 a dose, making it ‘realistic to roll out in many tens of millions of doses from now on,’ and it has high efficacy levels of around 75%-80% in young children.”

From CNN.

Financial Times | Noncommunicable Disease

Cell Therapy Offers Hope to Autoimmune Disease Patients

“A lupus diagnosis turned German teenager Janina Paech’s life on its head. Once a keen horse rider and an aspiring doctor, Paech’s heart, liver and kidneys were failing by the time she turned 21.

Running out of hope, her father Stefan reached out to Professor Georg Schett, a doctor on the other side of Germany, who was testing a cell-based gene therapy approved to treat blood cancer patients on lupus sufferers.

Paech became just the third patient to receive Car-T, or chimeric antigen receptor cell therapy, as a treatment for an autoimmune disease such as lupus, which is caused by the immune system attacking healthy cells. Within days of receiving the infusion, the crippling fatigue and joint pain that had blighted Paech’s early adulthood had dissipated. Three years later, she is still in remission…

The early findings offer hope to millions of autoimmune disease patients — four in every five of whom are women, probably due to genetic abnormalities associated with the X chromosome — who do not respond to conventional steroid treatment and face the threat of multiple organ failure.”

From Financial Times.